Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec AG and Apeiron Biologics have entered into a discovery collaboration to develop small molecules targeting a novel therapeutic concept for pain relief based on the research of professor Josef Penninger of the Austrian Academy of Sciences.
Subscribe to our email newsletter
During the initial phase of this collaboration, Apeiron Biologics and Evotec will jointly develop tailored biochemical and cellular assays, and Evotec will apply its skills in utilising such assays for ultra-high-throughput screening to identify promising hit molecules.
At a later stage, both companies aim to advance a selected lead compound into preclinical development up to proof-of-concept in patients. Commercialization rights which are shared equally may be out-licensed or assigned to a pharmaceutical partner.
“The top-level research provided by Apeiron and its scientific founder in this area, paired with Evotec’s substantial track record in the rapid identification of drug candidates and its expertise in field of central nervous system disorders is an excellent basis for successfully identifying novel pain therapeutics. This could become an attractive addition to our growing CNS pipeline,” said Dr Erich Greiner, executive vice president of science at Evotec.